JENSCARE SCIENTIFIC CO., LTD. Jenscare Scientific Co., Ltd. Stock
Equities
9877
CNE100005KC9
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.88 HKD | +2.65% |
|
-2.27% | -82.52% |
| Sales 2024 * | 178M 24.6M 192M | Sales 2025 * | 416M 57.35M 448M | Capitalization | 1.5B 207M 1.62B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 8.42 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3.61 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 376 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 62.9% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.65% | ||
| 1 week | -2.27% | ||
| Current month | -2.27% | ||
| 1 month | -20.49% | ||
| 3 months | -64.21% | ||
| 6 months | -75.32% | ||
| Current year | -82.52% |
1 week
3.71
4.17
1 month
3.715.15
Current year
3.1721.50
1 year
3.1745.00
3 years
3.1794.70
5 years
3.1794.70
10 years
3.1794.70
| Managers | Title | Age | Since |
|---|---|---|---|
Shi Wen Lv
CEO | Chief Executive Officer | 55 | 12-12-31 |
Yuan Yuan Li
DFI | Director of Finance/CFO | 38 | 20-11-30 |
Fei Pan
DFI | Director of Finance/CFO | 39 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ching Tan
BRD | Director/Board Member | 59 | 19-02-28 |
Jia Qi Zheng
BRD | Director/Board Member | 40 | 20-09-30 |
Fei Pan
DFI | Director of Finance/CFO | 39 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 3.88 | +2.65% | 3,735,682 |
| 24-06-06 | 3.78 | -2.58% | 1,885,000 |
| 24-06-05 | 3.88 | -1.27% | 1,404,200 |
| 24-06-04 | 3.93 | +0.51% | 1,178,600 |
| 24-06-03 | 3.91 | -1.51% | 1,158,200 |
Delayed Quote Hong Kong S.E., June 07, 2024 at 04:09 am EDT
More quotes
Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The Company develops interventional products for the treatment of structural heart disease. The Company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The Company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.599
CNY
Average target price
36.69
CNY
Spread / Average Target
+919.43%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -82.52% | 207M | |
| +16.65% | 133B | |
| -3.76% | 11.52B | |
| -4.86% | 8.3B | |
| +43.30% | 5.73B | |
| -22.44% | 4.69B | |
| +7.79% | 3.42B | |
| -17.26% | 2.54B | |
| -13.36% | 2.03B | |
| -16.39% | 1.86B |
- Stock Market
- Equities
- 9877 Stock
